Mangini Siobhan Nolan - 01 Jul 2022 Form 4 Insider Report for NGM BIOPHARMACEUTICALS INC

Role
President and CFO
Signature
/s/ Valerie Pierce, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
01 Jul 2022
Net transactions value
$0
Form type
4
Filing time
01 Jul 2022, 18:36:41 UTC
Previous filing
04 Mar 2022
Next filing
06 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NGM Stock Option (Right to Buy) Award $0 +100,000 $0.000000 100,000 01 Jul 2022 Common Stock 100,000 $12.78 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the stock option vest over a four-year period measured from from July 1, 2022, with 1/48th of the shares vesting on a monthly basis, subject to the reporting person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan) as of each such vesting date.